[转帖]定量分析cccDNA:抗病毒治疗期间临床和病毒应答关系

larrylarry

原文较长，现把总结部分摘录下来。有感兴趣的，我会分贴出来。

http://www.medscape.com/viewarticle/553013?src=mp

From Journal of Viral Hepatitis
Quantitative Analysis of HBV cccDNA from Clinical Specimens: Correlation
With Clinical and Virological Response During Antiviral Therapy
Posted 03/15/2007

E. J. Bourne1; J. L. Dienstag2; V. A. Lopez1; T. J. Sander3; J. M. Longlet3;
J. G. Hall3; R. W. Kwiatkowski3; T. Wright4; C. L. Lai5; L. D. Condreay1

Summary and Introduction

Summary
Attempts to investigate changes in various forms of intrahepatic hepatitis B
virus (HBV) DNA during antiviral therapy have been hampered by limitations
in technologies and scarcity of adequate tissue for analysis. We used a
sensitive, specific assay to detect and quantitate covalently closed
circular DNA (cccDNA) from total intrahepatic HBV DNA in clinical liver
specimens. Total HBV DNA and cccDNA from 21 needle-biopsy specimens were
quantified, with levels ranging from 0.1 to 9.8 copies/cell and 0.3 to 491.0
copies/cell, respectively. Then, we performed the same determinations on
baseline and week-52 liver needle-biopsy specimens from eight patients
enrolled in a clinical trial and evaluated the association between
intrahepatic HBV DNA levels and serological and virological endpoints. In
most patients, levels of intrahepatic HBV DNA, including cccDNA, decreased
over the 52-week study, regardless of therapy or serological outcome. Higher
ratios of cccDNA to total HBV DNA were detected at week 52 than at baseline
indicating a shift in predominance of nonreplicating virus in posttreatment
specimens. In patients who achieved treatment-related or spontaneous
hepatitis B e antigen (HBeAg) responses, including those harbouring
tyrosine-methionine-aspartate-aspartate-mutant HBV, levels of intrahepatic
and serum HBV DNA suppression were greater than those in patients without
HBeAg responses. In conclusion, this pilot study of intrahepatic HBV
replicative forms in patients with chronic hepatitis B indicated that total
intrahepatic and, specifically, cccDNA levels are not static but change as a
reflection of serological and virological events....

jonchan

我得英语水平不行，这是用google翻译的，希望能给大家一些帮助。

从定量分析JOURNAL病毒性肝炎临床标本中HBVcccDNA: 在临床和病毒学与抗病毒治疗的反应2007年3月15日张贴EJ真理观1; JLdienstag2; 甲诉洛佩斯1; J砂光3汤匙; Jlonglet3米; JG3大厅; 钢筋特约kwiatkowski3; 赖特4汤匙; 丙L荔5; L丁一简要介绍简要condreay试图改变查处各种形式的肝内乙型肝炎病毒(HBV) 抗病毒药物治疗期间的DNA就受到限制,组织充足的技术和稀缺进行分析. 我们用一个敏感、 具体分析和定量检测共价闭环DNA(cccDNA)从肝总肝内HBVDNA的临床标本. 共有来自21个乙肝DNA和cccDNA的针活检标本量化 以0.1至9.8级不等份/电池0.3至491.0拷贝/细胞,分别 然后 我们同样确定基线和演出周-52肝穿刺活检标本招收了8例临床试验 评估协会之间的肝内HBVDNA水平及血清病毒学和终点. 在大多数病人,肝内HBVDNA的水平,包括cccDNA的下降在52周的研究, 不论血清治疗或结果. cccDNA的比例更高占52周时HBVDNA的检测结果显示,超过基准转移 自是痘苗病毒病毒后处理标本. 在取得病人的治疗有关或自发乙肝e抗原(e抗原)反应,包括窝藏 酪氨酸-蛋氨酸-天冬氨酸-天冬氨酸 突变 乙肝、肝内和血清HBVDNA水平分别比抑制病人无抗原反应. 最后, 该项试验研究,在肝内乙肝病毒复制形式显示慢性乙型肝炎患者肝内总, 具体来说,cccDNA的水平没有变化,但作为一个静态的反映及血清病毒学事件::